Business
Cryoport Reports First Quarter 2025 Financial Results
Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.
About this update from Cryoport, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Supporting 711 global clinical trials as of March 31, 2025","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":306,"olType":false},{"type":"text","content":"NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.","length":282,"tagName":"p"},{"type":"image","alt":"Cryoport logo 2024","displaySize":"","headline":null,"caption":"Cryoport logo 2024","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/c9d39cb27d6dfd7627c75fe7c42ebcf6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DSUWR0bTe7hiioxV9QaBCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c9d39cb27d6dfd7627c75fe7c42ebcf6","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/371732/Cryoport___Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Jerrell Shelton, CEO of Cryoport, commented, "We delivered a strong start to the year with $41.0 million of revenue from continuing operations, which represented 10% year-over-year growth and drove meaningful improvement in adjusted EBITDA. We believe order patterns are stabilizing in our Life Sciences Products segment, while engagement levels increased significantly in our Life Sciences Services segment, highlighting a new momentum in our business. Consequently, we are optimistic in our outlook for the full year. Looking ahead, we continue to navigate through the current economic environment and, at this point in time, anticipate minimal impact from tariffs as we believe related charges will be passed through if and when they occur.","length":74...